210 related articles for article (PubMed ID: 35631512)
1. IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma.
Rechberger JS; Porath KA; Zhang L; Nesvick CL; Schrecengost RS; Sarkaria JN; Daniels DJ
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631512
[TBL] [Abstract][Full Text] [Related]
2. A novel interleukin-13 receptor alpha 2-targeted hybrid peptide for effective glioblastoma therapy.
Kurihara R; Horibe T; Shimizu E; Torisawa A; Gaowa A; Kohno M; Kawakami K
Chem Biol Drug Des; 2019 Jul; 94(1):1402-1413. PubMed ID: 30903640
[TBL] [Abstract][Full Text] [Related]
3. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
4. Targeting IL-13Rα2 for effective treatment of malignant peripheral nerve sheath tumors in mouse models.
Mrowczynski OD; Payne RA; Bourcier AJ; Mau CY; Slagle-Webb B; Shenoy G; Madhankumar AB; Abramson SB; Wolfe D; Harbaugh KS; Rizk EB; Connor JR
J Neurosurg; 2018 Nov; 131(5):1369-1379. PubMed ID: 30544352
[TBL] [Abstract][Full Text] [Related]
5. Analysis of biodistribution of intracranially infused radiolabeled interleukin-13 receptor-targeted immunotoxin IL-13PE by SPECT/CT in an orthotopic mouse model of human glioma.
Suzuki A; Leland P; Kobayashi H; Choyke PL; Jagoda EM; Inoue T; Joshi BH; Puri RK
J Nucl Med; 2014 Aug; 55(8):1323-9. PubMed ID: 24947060
[TBL] [Abstract][Full Text] [Related]
6. [Targeted therapy of malignant glioma by a chimeric fusion toxin composed of IL-13 and Pseudomonas exotoxin in vitro].
Zhang JJ; Weng RG; Liu J; Chen HP; Liu J; Ye H; Zheng WM
Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(11):731-4. PubMed ID: 22781350
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.
Heiss JD; Jamshidi A; Shah S; Martin S; Wolters PL; Argersinger DP; Warren KE; Lonser RR
J Neurosurg Pediatr; 2018 Dec; 23(3):333-342. PubMed ID: 30544335
[TBL] [Abstract][Full Text] [Related]
8. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway.
Bhardwaj R; Suzuki A; Leland P; Joshi BH; Puri RK
J Transl Med; 2018 Dec; 16(1):369. PubMed ID: 30572904
[TBL] [Abstract][Full Text] [Related]
10. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK
Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK
Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
Husain SR; Puri RK
J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
[TBL] [Abstract][Full Text] [Related]
16. A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy.
Sato Y; Vatsan R; Joshi BH; Husain SR; Puri RK
Curr Mol Med; 2023 Mar; ():. PubMed ID: 36999709
[TBL] [Abstract][Full Text] [Related]
17. Expression of IL-13Rα2 and FUS in glioma: clinicopathological and prognostic correlation.
Cheng G; Wang M; Zhang X; Zhang Y
BMC Neurol; 2023 May; 23(1):185. PubMed ID: 37158824
[TBL] [Abstract][Full Text] [Related]
18. IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma.
Kioi M; Shimamura T; Nakashima H; Hirota M; Tohnai I; Husain SR; Puri RK
Int J Cancer; 2009 Mar; 124(6):1440-8. PubMed ID: 19065664
[TBL] [Abstract][Full Text] [Related]
19. Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen.
Shimato S; Natsume A; Wakabayashi T; Tsujimura K; Nakahara N; Ishii J; Ito M; Akatsuka Y; Kuzushima K; Yoshida J
J Neurosurg; 2008 Jul; 109(1):117-22. PubMed ID: 18590440
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
Kawakami K; Kawakami M; Liu Q; Puri RK
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
